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N ew Treatment for Hypopigm entation 
In this iss ue, a g roup of resea rchers fro m Yale Uni versity Schoo l 
of Medicine reports a new method for restorin g pigmentation to 
areas of skin that lack it. Aaron Lerner, Ruth l--\alaban , Sidney 
~Iaus, and Gisela M oellmann arc g rowin g hum an melanocytes 
1I1 culture and then transplantin g them to hypopigmented areas 
of patients' skin . The melanocytes g row, and the sk in is repig-
mented. 
Lern er and hi s associates did th eir first mebnocy te transplan-
ta tion ex perim ent on a health y 33- yea r-o ld man with piebaldism. 
T hey took skin from his back w ith a shave biopsy and grew the 
melanocy tes in culture until they ex panded to 10 times their orig-
ina l number. This process tak es ·about 3 to 4 weeks. 
Next, Lern er and his coll eagues raised four suction blisters on 
the areas of the man 's chest that were devoid of pigment. They 
injected th e melanocy tes into the blisters, w hereupon the mela-
nocytes g rew and pig mented the area. Because th e melanocy tes 
were from the man 's own skin , the newly pigmented area w as a 
perfect match with the previously pig mented skin . 
Although Lerner thought the method sounded logica l before 
he tried it, he ex pected that the transplanted cells might not spread 
o ut over the hypopigmented area. " I thou ght I might get a ne-
vus," he rem arks. But, he concludes, melanocyte transplantation 
turn ed out to resemble bone marrow transplantion. The trans-
planted cell s "go right to w here they shou ld go." 
Lerner notes that thi s method is made possible by new meth ods 
that all ow inves ti gators to g row norm al melanocytes in culture. 
It is only in the past fi ve yea rs that resea rchers discove red that if 
th ey add tetradeca noy l-phorbol-l 3-acetate (TPA), a po tent tum or 
promoter, the cells wi ll g row. N ow resea rchers have suppl amed 
TPA w ith fibrob last g rowth factor. N either TPA nor fibroblast 
growth facto r is reported to malignantl y transform cell s. 
Since the results w ith the first patient were so promising, Lern er 
went on to trea t two mo re pat ients, one of whom has piebaldism , 
an d th e o ther vitiligo. He has furthe r simplified the method by 
inventing a new and much qui cker way than suction to separate 
the epidermis fro m th e de rmis, leaving a pocket in which to place 
cultured melanocytes. Encouraged by hi s success so fa r, Lern er 
says he wa nts to " rea ll y push ahead" and trea t many more pa-
tients. H e is co ll aboratin g with inves tigators at Howa rd Univer-
sity in Was hingto n, D.C. who see many black patients with 
viti ligo . 
Hope For Poison Ivy Sufferers 
M ice, like people, appear to be hyposensiti ve to urushiol for a 
short period of time after exposure to the compound. So it oc-
cu rred to Ian Dunn , Daniel Liberato, Jea n-Lu c Stampf, N ea l Cas-
tagnoli , and Vera Byers of the Unversity of California in San 
Francisco that perhaps this hyposensiti vity is caused by anti-idi-
otype antibodies , that is, ant ibod ies to antibodies. If so , it might 
be possible to develop an anti-idiotype " vaccine" to protect poi-
son iv y and poison oak sufferers. In this issue, they report on the 
firs t step in this in vest igation-the discovery that mice seem to 
ma ke a serum facto r, presumably an ant i-idiotype antibody , after 
exposure to urushi o l. 
T he researchers sensitized mice to urushiol by painting the 
substance on the an imal's abdomen. For the next 25 da ys, th e 
mice exhibited contact sensitivity to the substance: their ears swelled 
o n the subsequent painting with urushi ol. But after th e 25 da y 
peri od, the mi ce beca me hyposensiti ve, which las ted for about 
15 days . 
Castagnoli and his colleagues report that a factor present in th e 
animals' serum during this hyposensiti ve period suppressed con-
ta ct sensit ivity in other mice. T he suppressive factor disa ppea red 
by 40 da ys after the mice were sensiti zed and suppressed onl y 
contact sensiti vity to urushiol. The serum factor appears to be an 
antibody beca use it was present· in the imll1unoglobulin fraction 
of th e serum, and it co uld be nega ted if antibodies ro urushi o l 
were added to the serum . For th ese reasons, it appea rs to be an 
ant i-idiotype antibody. 
These results were so promising that Cas tagnoli and his col-
leagues next want to try th e sa me SOrt of experiment with hu-
mans. The volunteers , however, would receive oral doses of uru-
shiol, which wou ld induce hyposensitivity but would not ca use 
the typica l urushiol dermatitis . If humans, too , produce anti-
idiotype antibodies, it may be poss ible to exp loit that reacti on to 
protect against poison ivy. 
Follicular Melanogenesis and MSH 
A new group of synthetic melanocyte-stimulating hormones (MS H) 
appear to be far more potent and long-las tin g than the o ri ginal 
MS H , report N orman Levine, Athena Lemus-Wilson, Sterling 
Wood , Za lfa Malek, Fahad AI-Obeidi , Victo r Hruby, and Mac 
Hadley of the University of Arizona. If th e substances are as sa fe 
and effective in hum ans as they appear to be in mice, they could 
have "obvious clinica l appli ca tions," Lev ine says. The g roup re-
ports its resul ts in this issue. 
The synthetic hormones are on ly sub tl y different from MSH , 
accordin g to Levine. In one case, a single amino acid is substituted 
for another, and in another instance, an L-phenylalanine is sub-
stituted for the D form, indu cing a conformational change in th e 
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molccule. These synth eti c ho rm ones appea r to stimulate mel a-
nogenesis in the sa me way as natural MSH, but they are far mo re 
resistant to degradation by serum enzym es and sto mach acids, 
and, unex pectedl y for such large mo lecules , they pass throu gh 
the skin and are effecti ve locall y. 
Levine and hi s associates tested the melano tropins by admin-
istcrin g them to mi ce. They could determin e ve ry qui ckl y if the 
ho rm ones stimu lated melanogenesis; if they did, the mouse hair 
would darken. With this criterion, the resea rchers es tablished that 
th e synth eti c ho rm ones are effective w hen they are inj ected , givcn 
o rall y, or administered intra derm all y to mice. The topical admin-
istrati on ca uscd loca l darkenin g o f the mouse hair, whereas the 
oral ad mini stration or subcutaneous inj ections caused the m..ice to 
darken all o ver. 
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T he possible clinica l applica tio ns o f the melano tro pins could 
be to treat hypopigmentatio n di sorders , acco rdin g to Lev in e. But 
the synth cti c ho rm o nes could also conceivabl y have fa r morc 
wides pread appli cations. Peo ple w ho are just startin g to turn g ray 
could rub th e horm ones on their sca lp to resto re th eir natural hair 
color, fo r exa mple . O r persons w ho wanted to tan w itho ut going 
into th e sun co uld take an o ral dose o f the ho rm ones. 
Levine and his colleag ues are no w testing to see w heth er the 
ho rm ones arc as effecti ve in humans as they are in mi ce. The 
resea rchers are addin g the mel anotro pins to hum an skin grown 
in orga n culture and are g iving the horm ones to voluntcers to 
tes t th e toxicity o f these dru gs. So far, acco rdin g to Levine, the 
results look pro mising. But, of course, it is too ea rl y to say 
wh ether the mclano tropins will ful fi ll th eir initial pro mise. 
